Author: Rick Truax

Northbrook, Illinois, (October 30, 2023) – IDEX Corporation (NYSE:IEX) today announced that it has entered into a definitive agreement to acquire STC Material Solutions (“STC”), an integrated provider of advanced material science solutions, from Artemis for cash consideration of $206 million USD, subject to customary post-closing adjustments.

STC specializes in the design and manufacturing of technical ceramics and hermetic sealing products for the most extreme, mission critical applications. The company has relationships with leading manufacturers in the semiconductor, aerospace and defense, industrial technology, medical technology, and energy sectors. Headquartered in St. Albans, Vermont, STC also has operations in Santa Ana, California (USA).

“STC Material Solutions expands our growing expertise in material sciences and offers significant opportunities to collaborate with other IDEX critical components businesses on comprehensive solution sets for customers,” IDEX Chief Executive Officer and President Eric Ashleman said. “We see STC as an excellent fit with our growth strategy, possessing IDEX qualities throughout, including highly-engineered products developed and built with expertise that commands a premium.”

“We continue to prioritize the identification and completion of high-quality acquisitions like this. Our extended M&A team has developed a strong funnel of excellent prospective additions that will continue to put our strong balance sheet to work,” Ashleman said.

STC is expected to generate approximately $50 million in revenue in 2024, with IDEX-like margins and will be included in the Health & Science Technologies (HST) segment.

IDEX expects the transaction to close by late-2023, subject to regulatory approvals. This acquisition is expected to be funded by IDEX using cash on hand and proceeds from its revolving credit facility.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements include statements regarding the expected benefits of the acquisition of STC, the expected impact of the acquisition on IDEX’s product offerings or proposed product offerings and pricing, the enhancement of IDEX’s business strategy, integration plans, the expected growth opportunities and synergies resulting from the acquisition, the projected earnings and margins of STC and the related impact on IDEX’s earnings, future acquisitive behavior and pipeline of IDEX, and the expected timing and funding for the closing of the acquisition, and are indicated by words or phrases such as “anticipates,” “estimates,” “plans,” “expects,” “projects,” “forecasts,” “should,” “could,”

“will,” “management believes,” “the Company believes,” “the Company intends” and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those anticipated at the date of this press release. The risks and uncertainties include, but are not limited to, the following: levels of industrial activity and economic conditions in the U.S. and other countries around the world, including uncertainties in the financial markets and adverse developments affecting the financial services industry; pricing pressures, including inflation and rising interest rates, and other competitive factors and levels of capital spending in certain industries, all of which could have a material impact on order rates and IDEX’s results; the impact of health epidemics and pandemics and terrorist attacks and wars, which could have an adverse impact on IDEX’s business by creating disruptions in the global supply chain and by potentially having an adverse impact on the global economy; IDEX’s ability to make acquisitions and to integrate and operate acquired businesses on a profitable basis; the relationship of the U.S. dollar to other currencies and its impact on pricing and cost competitiveness; political and economic conditions in foreign countries in which IDEX operates; developments with respect to trade policy and tariffs; capacity utilization and the effect this has on costs; labor markets; supply chain conditions; market conditions and material costs; risks related to environmental, social and corporate governance issues, including those related to climate change and sustainability; and developments with respect to contingencies, such as litigation and environmental matters. Additional factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, the risks discussed in the “Risk Factors” section included in IDEX’s most recent annual report on Form 10-K and IDEX’s subsequent quarterly reports filed with the Securities and Exchange Commission (“SEC”) and the other risks discussed in IDEX’s filings with the SEC. The forward-looking statements included here are only made as of the date of this press release, and management undertakes no obligation to publicly update them to reflect subsequent events or circumstances, except as may be required by law. Investors are cautioned not to rely unduly on forward-looking statements when evaluating the information presented here.

About IDEX

IDEX Corporation (NYSE: IEX) makes thousands of products and mission-critical components that improve everyday life all around you. If you enjoy chocolate, it quite possibly passed through a Viking® internal gear pump at the candy factory. If you were ever in a car accident, emergency workers may have used the Hurst Jaws of Life® rescue tool to save your life. If your doctor ordered a DNA test to predict your risk of disease or determine a course of treatment, the lab may have used equipment containing components made by IDEX Health & Science. Founded in 1988 with three small, entrepreneurial manufacturing companies, we’re proud to say that we now call over 50 diverse businesses around the world part of the IDEX family. With more than 8,500 employees and manufacturing operations in more than 20 countries, IDEX is a high-performing, global company with over $3.1 billion in annual sales, committed to making trusted solutions that improve lives. IDEX shares are traded on the New York Stock Exchange under the symbol “IEX”.

For further information on IDEX Corporation and its business units, visit the company’s website at www.idexcorp.com.

Investor Contact

IDEX Corporation Allison Lausas

Vice President, Chief Accounting Officer and Interim Chief Financial Officer

+1 847-498-7070

investorrelations@idexcorp.com

Media Contact:

IDEX Corporation

Mark Spencer

+1 847-457-3793 mdspencer@idexcorp.com

NORTHBROOK, IL (October 25, 2023) – IDEX Corporation (NYSE:IEX) today announced the appointment of Abhi Khandelwal as Senior Vice President and Chief Financial Officer of the Company, effective November 20, 2023.

Mr. Khandelwal returns to IDEX where he served from 2010 to early 2020 in a number of financial roles of increasing responsibility, most recently as Vice President of Finance Operations, Treasury and Financial Planning & Analysis. He joins IDEX after serving as Chief Financial Officer of Multi-Color Corporation, a global packaging services and label solutions provider based in Rosemont, Illinois since January 2022, and, prior to that, as Senior Vice President and Chief Financial Officer for CIRCOR International.

Prior to his initial service with IDEX, Mr. Khandelwal held a range of financial leadership positions at Stanley Black & Decker and General Electric. He earned a Bachelor of Science degree in Finance from Indiana University and a Master of Business Administration degree from Northwestern University.

“We are thrilled to welcome Abhi back to IDEX, where he will be able to leverage his CFO experience along with his successful prior history with our organization and our people. He was a trusted financial partner to me in my earlier role as COO, and I look forward to his expertise and partnership in helping IDEX continue to grow,” IDEX CEO and President Eric Ashleman said.

Allison Lausas, who has served as the Company’s interim Chief Financial Officer since September 2023, will cease serving as interim Chief Financial Officer as of the effective date of Mr. Khandelwal’s appointment, and will continue in her position as Vice President and Chief Accounting Officer. Mr. Ashleman stated, “I want to thank Allison for her outstanding leadership in this interim period and for the talent and leadership she brings to our finance team overall. We are fortunate to have her on the team, and I am very appreciative of her contributions to IDEX, especially in this time of transition.”

About IDEX

IDEX (NYSE: IEX) makes thousands of products and mission-critical components that improve everyday life all around you. If you enjoy chocolate, it quite possibly passed through a Viking® internal gear pump at the candy factory. If you were ever in a car accident, emergency workers may have used the Hurst Jaws of Life® rescue tool to save your life. If your doctor ordered a DNA test to predict your risk of disease or determine a course of treatment, the lab may have used equipment containing components made by IDEX Health & Science. Founded in 1988 with three small, entrepreneurial manufacturing companies, we’re proud to say that we now call over 50 diverse businesses around the world part of the IDEX family. With more than 8,500 employees and manufacturing operations in more than 20 countries, IDEX is a high-performing, global company with over $3.1 billion in annual sales, committed to making trusted solutions that improve lives. IDEX shares are traded on the New York Stock Exchange under the symbol “IEX.”

For further information on IDEX Corporation and its business units, visit the company’s website at www.idexcorp.com.

Investor Contact:
IDEX Corporation
Allison Lausas
Vice President and Chief Accounting Officer
+1 847-498-7070
investorrelations@idexcorp.com

Media Contact:
IDEX Corporation
Mark Spencer
+1 847-457-3793
mdspencer@idexcorp.com

Third Quarter 2023 Highlights

(All comparisons are against the third quarter of 2022 unless otherwise noted)

• Sales of $793.4 million, down 4% overall and 6% organically
• Reported diluted EPS of $2.75, up 17%, and adjusted diluted EPS of $2.12, down 1%, included a lower effective tax rate
• Strong operating cash flow of $227 million, up 14%; record free cash flow of $207 million, up 14%
• Divested Micropump, Inc. for $110 million in cash, resulting in gain of $71 million, net of taxes
• Full year GAAP EPS guidance raised to $7.91 to $7.96 from prior guidance of $6.80 to $6.90
• Full year adjusted EPS guidance raised to $8.13 to $8.18 from prior guidance of $7.90 to $8.00

NORTHBROOK, IL, October 25, 2023 – IDEX Corporation (NYSE: IEX) today announced its
financial results for the three month period ended September 30, 2023.

“IDEX delivered strong profitability and achieved record free cash flow in the third quarter,” said Eric D.
Ashleman, IDEX Corporation Chief Executive Officer and President. “Our teams continue to execute for
customers and shareholders in a dynamic environment of transition and recalibration.”

“We believe the divergent rates of destocking in our end markets have largely run their course, returning
us to more typical backlog and lead time levels. Our focus is to leverage our 8020 philosophy and
disproportionately allocate resources to those application niches with the highest potential.”

“We remain dedicated to our long-term focus as we continue to aggressively deploy capital to support
organic growth and M&A. Our balance sheet has ample capacity to deliver on our goals, and our funnel
of potential acquisitions remains strong and of high quality.”

2023 Outlook

Full year 2023 organic sales are projected to decline 1% to 2% over the prior year, with GAAP diluted
EPS of $7.91 – $7.96 (adjusted diluted EPS of $8.13 – $8.18).
Fourth quarter 2023 organic sales are projected to decline 8% to 9% over the prior year period, with
GAAP diluted EPS of $1.50 – $1.55 (adjusted diluted EPS of $1.74 – $1.79).

Full Press Release

(All comparisons against the first quarter of 2022 unless otherwise noted)

First Quarter 2023 Highlights

Record sales of $845 million, up 13% overall and 6% organically
Reported EPS of $1.84, up 1% and adjusted EPS of $2.09, up 7%
Strong operating cash flow of $148 million, up 86%; free cash flow of $121 million, up 91%
Reached agreement in April 2023 to purchase Iridian Spectral Technologies

NORTHBROOK, Ill.–(BUSINESS WIRE)–Apr. 26, 2023– IDEX Corporation (NYSE: IEX) today announced its financial results for the three month period ended March 31, 2023.

“IDEX delivered strong results in the first quarter,” said Eric D. Ashleman, IDEX Corporation Chief Executive Officer and President. “We achieved record sales with positive organic growth across all three of our segments, earnings per share above the high end of our guidance, and strong free cash flow. Strength in our Fluid & Metering Technologies and our Fire & Safety / Diversified Products businesses provided near-term mitigation against the impacts of the anticipated inventory correction experienced within our Health & Science Technologies businesses.”

“As we progressed through the quarter, customers across our Health & Science Technologies segment indicated a larger, more prolonged inventory correction than previously communicated. End market demand is still positive, but we believe our customers have sufficient inventory of our critical components to support that demand. With the revised 2023 revenue growth outlook for Health & Science Technologies now negative, we have proactively executed targeted cost reductions to offset a portion of this pressure. Based on our current outlook, we are lowering our full year 2023 adjusted EPS guidance to $8.25 to $8.55 per share.”

“The markets served by our Health & Science Technologies businesses have strong fundamental secular growth trends. We remain well-positioned, solving difficult problems with customers on the cutting edge of new technologies, and our organic and inorganic pipeline supports our aspirations to deliver outstanding business performance.” Ashleman continued, “We continue to execute on our strong M&A strategy and are excited to announce our intent to acquire Iridian Spectral Technologies for 150 million Canadian dollars. This highly strategic asset brings capabilities that expand our optical filters portfolio serving the space, life science and telecommunications markets. We expect this transaction to close in the second quarter, subject to customary closing conditions.”

2023 Outlook

Full year 2023 organic sales growth is projected to be 0 to 3 percent over the prior year period, with GAAP EPS of $7.30 to $7.60 (adjusted EPS of $8.25 to $8.55).

Second quarter 2023 organic sales growth is projected to be approximately 3 percent, with GAAP EPS of $1.86 to $1.89 (adjusted EPS of $2.10 to $2.13).

Full Press Release

Northbrook, Illinois, (April 26, 2022) – IDEX Corporation (NYSE:IEX) today announced it has entered into a definitive agreement to acquire Iridian Spectral Technologies (“Iridian”) for cash consideration of 150 million Canadian dollars (“CAD”), subject to customary adjustments. The acquisition complements existing IDEX optical coating expertise, allowing IDEX to expand its core capabilities to support current and future markets.

Iridian is a global leader in designing and manufacturing thin-film, multi-layer optical filters serving the laser communications, telecommunications, and life sciences markets. The purchase is expected to close later this quarter, subject to customary closing conditions, at which point Iridian will join the businesses of IDEX Optical Technologies in IDEX’s Health & Science Technology segment. Iridian will also be a strong partner in the life science filters business driven by the Semrock team of IDEX Health & Science.

“This acquisition strongly supports our strategic growth plan,” IDEX Chief Executive Officer and President Eric Ashleman said. “It expands our talent, technology and product portfolio in optical filters, enabling us to better compete in our core markets, and expand into new markets that we believe will drive profitable growth.”

Iridian has proven expertise in optical filter design and production, providing support throughout a product’s lifecycle, from initial prototyping to high-volume manufacturing. They offer advanced, proprietary thin-film design deposition and manufacturing technology of durable, high-performance filter optics.

Iridian has a strong brand reputation and an established, loyal customer base, which complements the IDEX Optical Technology brands (CVI Laser Optics, CVI Infrared Optics, and Advanced Thin Films) along with the IDEX Health & Science, Semrock optical filters product line.

Privately held and based in Ottawa, Ontario, Canada, Iridian expects fiscal year 2023 sales of approximately CAD 36 million and EBITDA margin in the low 30s.

Use of Non-GAAP Financial Information

IDEX prepares its public financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP). IDEX supplements certain GAAP financial performance metrics with non-GAAP financial performance metrics. Management believes these non-GAAP financial performance metrics provide investors with greater insight, transparency and a more comprehensive understanding of the financial information used by management in its financial and operational decision-making because certain of these non-GAAP metrics exclude items not reflective of ongoing operations. Non-GAAP financial performance metrics should not be considered a substitute for, nor superior to, the financial data prepared in accordance with GAAP. EBITDA is calculated as net income plus interest expense plus provision for income taxes plus depreciation and amortization. EBITDA margin is calculated as EBITDA divided by net sales.

IDEX has not provided a reconciliation of the expected EBITDA margin of Iridian for FY 2023 because we are unable to quantify certain amounts that would be required to be included in Iridian’s contribution to net income without unreasonable efforts. In addition, IDEX believes such reconciliation would imply a degree of precision that would be confusing or misleading to investors.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements include statements regarding the expected benefits of the acquisition of Iridian, the expected impact of the acquisition on IDEX’s product offerings or proposed product offerings, the enhancement of IDEX’s business strategy, integration plans, expected growth opportunities, the projected sales and EBITDA margin of Iridian, and the expected timing for the closing of the acquisition. These statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those anticipated at the date of this press release. The risks and uncertainties include, but are not limited to, the following: levels of industrial activity and economic conditions in the U.S. and other countries around the world, including uncertainties in the financial markets and adverse developments affecting the financial services industry; pricing pressures, including inflation and rising interest rates, and other competitive factors and levels of capital spending in certain industries, all of which could have a material impact on order rates and IDEX’s results; the impact of health epidemics and pandemics and terrorist attacks and wars, including the ongoing conflict between Russia and Ukraine, which could have an adverse impact on IDEX’s business by creating disruptions in the global supply chain and by potentially having an adverse impact on the global economy; IDEX’s ability to integrate Iridian and to acquire, integrate and operate other acquired businesses on a profitable basis; the relationship of the U.S. dollar to other currencies and its impact on pricing and cost competitiveness; political and economic conditions in foreign countries in which IDEX operates; developments with respect to trade policy and tariffs; interest rates; capacity utilization and the effect this has on costs; labor markets; supply chain backlogs, including risks affecting component availability, labor inefficiencies and freight logistical challenges; market conditions and material costs; risks related to environmental, social and corporate governance issues, including those related to climate change and sustainability; and developments with respect to contingencies, such as litigation and environmental matters. Additional factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, the risks discussed in the “Risk Factors” section included in IDEX’s most recent annual report on Form 10-K and IDEX’s subsequent quarterly reports filed with the Securities and Exchange Commission (“SEC”) and the other risks discussed in IDEX’s filings with the SEC. The forward-looking statements included here are only made as of the date of this press release, and management undertakes no obligation to publicly update them to reflect subsequent events or circumstances, except as may be required by law. Investors are cautioned not to rely unduly on forward-looking statements when evaluating the information presented here.

About IDEX

IDEX Corporation (NYSE: IEX) makes thousands of products and mission-critical components that improve everyday life all around you. If you enjoy chocolate, it quite possibly passed through a Viking® internal gear pump at the candy factory. If you were ever in a car accident, emergency workers may have used the Hurst Jaws of Life® rescue tool to save your life. If your doctor ordered a DNA test to predict your risk of disease or determine a course of treatment, the lab may have used equipment containing components made by IDEX Health & Science. Founded in 1988 with three small, entrepreneurial manufacturing companies, we’re proud to say that we now call over 50 diverse businesses around the world part of the IDEX family. With more than 8,500 employees and manufacturing operations in more than 20 countries, IDEX is a high-performing, global company with over $3.1 billion in annual sales, committed to making trusted solutions that improve lives. IDEX shares are traded on the New York Stock Exchange under the symbol “IEX”.

For further information on IDEX Corporation and its business units, visit IDEX’s website at www.idexcorp.com.

Investor Contact

IDEX Corporation
Allison Lausas
Vice President and Chief Accounting Officer
+1 847-498-7070
investorrelations@idexcorp.com

Media Contact:

IDEX Corporation
Mark Spencer
+1 847-457-3793
mdspencer@idexcorp.com